The front page of AI-driven biology
Thursday, October 15, 2026Thu, Oct 15
Updated 6:32 PM PT
RegCell closed a $44 million Series A round led by Playground Global alongside non-dilutive grants from Japan's Agency for Medical Research and Development, bringing total financing to $66 million.
In a Phase 3 trial in China, MediLink and Roche's antibody-drug conjugate tambotatug pelitecan extended median overall survival in relapsed small cell lung cancer to 13.3 months compared with 9.4 months on topotecan chemotherapy.
Electra Therapeutics aims to raise net proceeds of $296.6 million, rising up to $341.9 million if underwriters exercise their option, by offering 21.7 million shares priced between $14 and $16 each, matching the reported $342 million goal.
In an early-stage clinical trial, Corbus Pharmaceuticals' experimental pill CRB-913 achieved up to 5% placebo-adjusted weight loss after 12 weeks without the prominent neuropsychiatric safety issues that derailed earlier drugs in its class.
The Food and Drug Administration has approved Curium's Bexlutry, clearing the first generic radioligand therapy equivalent to Novartis' Lutathera.
Camizestrant, an oral selective estrogen receptor degrader, failed to outperform standard care at delaying disease progression when paired with another therapy in a pivotal Phase 3 trial for advanced breast cancer.
Cellectis is seeking partners to offload its clinical-stage donor-derived cell therapies for leukemia and lymphoma, lasme-cel and eti-cel, effectively ending its pioneering work in allogeneic CAR-T treatments.
Akeso and Summit Therapeutics reported that their bispecific antibody targeting PD-1 and VEGF extended median overall survival to 30.8 months compared with 22.6 months for pembrolizumab in the Phase 3 HARMONi-2 trial in non-small cell lung cancer.
ProtScape combines global protein interaction data, single-cell gene expression, and protein language models to reconstruct context-specific protein interactomes across more than 200 cell types.
Computational biologists developed a multistate design framework that optimizes enzyme active sites across an entire reaction pathway rather than modeling a single rigid transition state.
Researchers tested multi-eGO, an atomistic simulation model developed for small molecules, on binding between the human PDZ2 protein domain and an experimental peptide.
LucaCell is a single-cell foundation model that encodes transcriptomic features through pre-trained mRNA nucleotide sequence embeddings rather than fixed gene names, allowing it to translate across species without manual ortholog mapping.
Therna Biosciences has released public datasets from its Chronos platform profiling roughly 60,000 synthetic regulatory elements across approximately 50 pooled cell lines.